Show simple item record

dc.contributor.authorAlvi, Muhammad A.
dc.contributor.authorLoughrey, Maurice B.
dc.contributor.authorDunne, Philip
dc.contributor.authorMcQuaid, Stephen
dc.contributor.authorTurkington, Richard
dc.contributor.authorFuchs, Marc-Aurel
dc.contributor.authorMcGready, Claire
dc.contributor.authorBingham, Victoria
dc.contributor.authorPang, Brendan
dc.contributor.authorMoore, Wendy
dc.contributor.authorMaxwell, Perry
dc.contributor.authorLawler, Mark
dc.contributor.authorJames, Jacqueline A.
dc.contributor.authorMurray, Graeme I.
dc.contributor.authorWilson, Richard H.
dc.contributor.authorSalto-Tellez, Manuel
dc.date.accessioned2017-06-13T08:00:12Z
dc.date.available2017-06-13T08:00:12Z
dc.date.issued2017-07-11
dc.identifier.citationAlvi , M A , Loughrey , M B , Dunne , P , McQuaid , S , Turkington , R , Fuchs , M-A , McGready , C , Bingham , V , Pang , B , Moore , W , Maxwell , P , Lawler , M , James , J A , Murray , G I , Wilson , R H & Salto-Tellez , M 2017 , ' Molecular profiling of signet ring cell colorectal cancer provides a strong rationale for genomic targeted and immune checkpoint inhibitor therapies ' , British Journal of Cancer , vol. 117 , no. 2 , pp. 203-209 . https://doi.org/10.1038/bjc.2017.168en
dc.identifier.issn0007-0920
dc.identifier.otherPURE: 101664644
dc.identifier.otherPURE UUID: d541416b-7bea-4331-825c-0bec5ec35755
dc.identifier.otherPubMed: 28595259
dc.identifier.otherScopus: 85027058602
dc.identifier.urihttp://hdl.handle.net/2164/8800
dc.descriptionWe would like to thank all patients whose samples were used in this study. We are also thankful to the Northern Ireland Biobank and Grampian Biorepository for providing us with tissue blocks and patient data; and Dr HG Coleman (Queen’s University Belfast) for her advice on statistical analyses. This work has been carried out with financial support from Cancer Research UK (grant: C11512/A18067), Experimental Cancer Medicine Centre Network (grant: C36697/A15590 from Cancer Research UK and the NI Health and Social Care Research and Development Division), the Sean Crummey Memorial Fund and the Tom Simms Memorial Fund. The Northern Ireland Biobank is funded by HSC Research and Development Division of the Public Health Agency in Northern Ireland and Cancer Research UK through the Belfast CRUK Centre and the Northern Ireland Experimental Cancer Medicine Centre; additional support was received from Friends of the Cancer Centre. The Northern Ireland Molecular Pathology Laboratory which is responsible for creating resources for the Northern Ireland Biobank has received funding from Cancer Research UK, Friends of the Cancer Centre and Sean Crummey Foundation.en
dc.format.extent7
dc.language.isoeng
dc.relation.ispartofBritish Journal of Canceren
dc.rightsThis work is licensed under the Creative Commons Attribution-Non-Commercial-Share Alike 4.0 International License. To view a copy of this license, visit http:// creativecommons.org/licenses/by-nc-sa/4.0/en
dc.subjectKITen
dc.subjectgenotypeen
dc.subjectPDL1en
dc.subjectR Medicineen
dc.subjectCancer Research UKen
dc.subjectC11512/A18067en
dc.subjectC36697/A15590en
dc.subject.lccRen
dc.titleMolecular profiling of signet ring cell colorectal cancer provides a strong rationale for genomic targeted and immune checkpoint inhibitor therapiesen
dc.typeJournal articleen
dc.contributor.institutionUniversity of Aberdeen.Institute of Medical Sciencesen
dc.contributor.institutionUniversity of Aberdeen.Applied Medicineen
dc.description.statusPeer revieweden
dc.description.versionPublisher PDFen
dc.identifier.doihttps://doi.org/10.1038/bjc.2017.168


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record